J. Greg Davis - President and Chief Executive Officer

J. Greg Davis, the President and Chief Executive Officer joined Tryton in 2008, prompting Tryton’s move to North Carolina.

Mr. Davis is an experienced medical device executive with broad global and functional experience in finance, manufacturing, sales and general management. Prior to joining Tryton Medical, Mr. Davis was president of Guidant Japan with P&L responsibility for the company’s $225 million cardiovascular business. Prior to his work in Japan, Mr. Davis managed Guidant’s product portfolio in 13 Asian countries. He was also instrumental in the start up and management of an FDA-regulated, Class III manufacturing facility in Dorado, Puerto Rico. Mr. Davis started his career in various financial management roles with Cardiac Pacemakers Incorporated and Eli Lilly in the U.S. and Puerto Rico.

Mr. Davis holds a B.S. in mechanical engineering from the University of Minnesota and an M.B.A. from the University of Michigan. Mr. Davis is the Chairman of the Board for ibiliti, a non-profit organization created to accelerate the growth and commercialization of advanced medical technologies in North Carolina.

Aaron V. Kaplan, M.D., F.A.C.C., F.S.C.A.I.

Dr. Aaron V. Kaplan is Professor of Medicine and of Community & Family Medicine and Director, Dartmouth Device Development Symposia at Dartmouth Medical School and Director of Research, Cardiac Catheterization Laboratories at the Dartmouth-Hitchcock Medical Center in Lebanon, N.H. In addition to his clinical responsibilities, Dr. Kaplan supervises cardiology fellows, chairs the Dartmouth Device Development Symposia and lectures regularly at the Tuck School. Prior to joining the Dartmouth Faculty, Dr. Kaplan was director of Interventional Cardiology at the Palo Alto VA and served on the faculty at Stanford. Dr. Kaplan has more than 40 publications and is on the editorial board of Cardiac Catheterization and Intervention.

Dr. Kaplan has been an active medical device entrepreneur for more than 15 years and has been on the founding team of a number of venture-backed medical device companies including LocalMed and Perclose. In addition, Dr. Kaplan has consulted to NMT Medical, Guidant Corporation, Johnson & Johnson and was an Entrepreneur-In-Residence at Three Arch Partners. Dr. Kaplan has authored 18 U.S. Patents.

He received a B.S. from Tufts University, M.D. at Wake Forest University, medical training at Northwestern University and cardiology training at Stanford University.

H. Richard Davis – Chief Technical Officer

Richard Davis has more than 15 years of medical device experience, primarily in the areas of general management, product development, clinical research, and operations. Throughout his career he has developed several coronary and peripheral stent designs, taking them from concept to clinical evaluation to regulatory approval and sales.

Prior to joining Tryton, Richard held positions at Cordis, a Johnson & Johnson company, and Orbus Medical Technologies. During his eight years at Orbus Richard founded and directed the company’s European operations, including the design and formation of manufacturing facilities, sales and marketing, regulatory affairs, and clinical research groups. While at Cordis he led a team of representatives from clinical research, regulatory affairs, product development and manufacturing. During his tenure there he was responsible for transferring technology from plants in New Jersey and Miami to Roden, the Netherlands.

Richard holds an M.S. in Mechanical Engineering from the Florida International University.

Brett Farabaugh – Chief Financial Officer

Brett Farabaugh has a diverse background working with entrepreneurial companies in the public and private arenas. Prior to Tryton Medical, Brett held the position of chief financial officer for StrikeIron, Inc., a venture-backed web-based data delivery company. Prior to StrikeIron, Farabaugh served as chief financial officer of Icoria, Inc. (formerly Paradigm Genetics, Inc.), a publicly traded biotech company acquired by Clinical Data, Inc. in 2005. Brett also held the role of vice president of finance for Nuada Pharmaceuticals, Inc. Prior to joining Nuada Pharmaceuticals, Mr. Farabaugh served for 12 years in various positions at PricewaterhouseCoopers (PwC), most recently as senior manager of the global technology industry group.

Mr. Farabaugh’s experience includes financial management, analysis and reporting, initial public offerings and other exit strategies, extensive due diligence related to investment and acquisitions and fundraising in both the public and private markets.

Mr. Farabaugh earned his degree in Accounting from the University of Virginia.

Olivier Delporte – Vice President, Sales & Marketing, Europe

Olivier Delporte is an international executive with 10 years of sales and marketing experiences in various sectors and significant medical device experience in Europe.

Olivier led a group overseeing Abbott Vascular’s drug eluting stent product line in Europe, the Middle East and Africa as DES Marketing Manager, EMEA. In that role Olivier and his team successfully launched the XIENCE V™ Stent System in the EMEA region, making it one of the two leading DES products in the area. Prior to that he held various European marketing and sales positions, including European Product Manager for the MULTI-LINK FRONTIER, Guidant’s bifurcation stent system.

Olivier has worked and studied in the United States, France, Spain, and Belgium. He earned a Commercial Engineering Degree from the Université Catholique de Louvain, Belgium, and an M.B.A. from the University of Chicago.

Douglas Ferguson – Vice President, Regulatory & Clinical

Douglas Ferguson has more than 18 years of medical device experience, working in the areas of regulatory and clinical affairs, compliance, research and development, and quality assurance. Douglas has brought a wide variety of products from early development to commercialization via simple and complex regulatory/clinical pathways to gain worldwide regulatory approvals.

Prior to joining Tryton, Douglas held positions at Becton Dickinson and Company, Boston Scientific Corporation, and C.R. Bard, Inc. While at Boston Scientific Corporation, Douglas spearheaded the effort to bring the company’s first drug eluting stent to worldwide markets, starting at the time of the first-in-man trial and serving as the principal liaison with the FDA and European notified body in obtaining approvals for this combination product. He also played a significant role in finalizing the company’s overall approach to creating global regulatory/clinical strategies, incorporating risk identification and minimization to facilitate timely approvals.

Douglas holds a B.S. degree in Biomedical Engineering from the Johns Hopkins University and an M.S. degree in Biomedical Engineering from the University of Alabama at Birmingham.